High-grade gliomas account for 35 to 46% of all central nervous system tumors. Despite combination therapy, the overall 5-year survival rate does not exceed 10%. The emergence of innovative immunotherapeutic strategies was the beginning of a new direction in the treatment of this category of patients. The paper describes a clinical case of a patient with the third recurrent glioblastoma multiforme (GBM). The immunotherapy protocol included the combined administration of an autologous dendritic cell-based vaccine and repeated intrathecal/intraventricular injections of donor allogeneic immunocompetent cells for 3 years. The patient is in remission without any therapy within 13.3 years after starting immunotherapy. No side effects were observed. Thus, immunotherapy may be an option for the treatment of patients with high-grade malignant gliomas refractory to conventional therapy and deserves further study.